Indian Pharma Lobby Says Delhi High Court Exceeded Its Authority In Restraining Hetero Dasatinib Application Due To BMS Petition
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The recent decision of the Delhi High Court restraining the Drug Controller General of India from approving Hetero's dasatinib has drawn flak from the Indian Pharmaceutical Alliance - a group that represents the most influential Indian drug companies. The court had barred India's drug regulatory agency from approving Hetero's application on a petition filed by Bristol-Myers Squibb, maker of the brand drug Sprycel